Concinnity Genetics – a spin out from the University of Edinburgh

Concinnity Genetics uses unique AI technology to build gene control systems that improve the safety of gene therapies. The Edinburgh University spin out raised £3 million in late 2024 in an oversubscribed seed funding round that included the University of Edinburgh’s in-house venture investment fund. The investment was led by Eos Advisory with participation from Scottish Enterprise, OCC and Maven Capital Partners. 

Concinnity Genetics is co-founded by bioengineers CEO Jessica Birt and CSE Dr Matthew Dale, both from Professor Susan Rosser’s UK Centre for Mammalian Synthetic Biology. Engineering biology is a major strength of the University of Edinburgh, catalysing novel solutions across three mission areas – future of health and care, data and AI for good, and climate and sustainability. 

Gene therapies have the potential to revolutionise health care by treating or even curing a variety of intractable diseases, but they need to be delivered precisely into the body to avoid side effects. Concinnity’s novel, RNA-based systems enable the precise control of gene therapies even after dosing, conveying the ability to respond to and reduce their own side effects as well as improve the efficacy of these innovative treatments. 

Co-founder and CEO, Jessica Birt said:

“We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible”.